Prof. Dr. med. Klaus Pantel 

C3 professorship 

Date of birth: 3. August 1960, male 

Professor, Director, Institute of Tumor Biology 

Universitätsklinikum Hamburg-Eppendorf 

Hamburg, Martinistrasse 52, 20246 Hamburg 

Phone: +49 7410 53503, E-Mail: pantel@uke.de 

Academic Education and Graduation 

1995 Habilitation in Immunology. LMU Munich 

1987-1989 DFG-Postdoctoral fellow, Wayne-State University, Detroit, USA 

1985- 1987 Dr. med. thesis, University Cologne Subject: Mathematical Modeling  

1980-1986 Studies of Medicine, University Cologne 

Professional Career 

2016 – 2023 Adjunct Professor of Medicine, University of Bergen, Norway 

Since 2015 Member of the Executive Board of the University Cancer Center Hamburg 

Since 2002 Director & C4 Professor, Institute of Tumor Biology, UKE, Hamburg, Germany 

1999 – 2002 C3 Professor, Molecular Genetics in Gynecology, UKE (Germany) 

1989-1998 Faculty Researcher, Group leader, Institute of Immunology LMU Munich 

Awards and Leadership 

2023 Coordinator of the Cancer Mission EU Network project PANCAID 

2023 Coordinator of the EU/IHI consortium GUIDE.MRD 

2020 Founder & Coordinator of the ELBS consortium (www.elbs.eu) 

2019 ERC (European Research Council) Advanced Investigator Grant Award INJURMET 

2014 ERC (European Research Council) Advanced Investigator Grant Award DISSECT 

2015 Coordinator of the EU/IMI Network CANCER-ID 

Since 2017   Member of the Steering Committee of the DFG SPP microBONE 

2010 AACR Outstanding Investigator Award for Breast Cancer Research, San Antonio 

2010 German Cancer Award 2010 (Translational Area), Berlin 

Top five publication within the last 5 years: 

1. Stadler JC, Keller L, …, Klaus Pantel*, Gebhardt C*, Schneider SW*. Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors. J Immunotherapy of Cancer 2023 May;11(5):e006456. (*shared authors) 

1. Hofbauer LC, Bozec A, Rauner M, Jakob F, Perner S, Pantel K. Novel approaches to target the microenvironment of bone metastasis. Nature Rev Clin Oncol 2021. 

1. Koch C, Kuske A, Joosse SA, Yigit G, Sflomos G, Thaler S, Smit DJ, Werner S, Borgmann K, Gartner S, Mossahebi Mohammadi P, Battista L, Cayrefourcq L, Altmuller J, Salinas-Riester G, Raithatha K, Zibat A, Goy Y, Ott L, Bartkowiak K, Tan TZ, Zhou Q, Speicher MR, Muller V, Gorges TM, Jucker M, Thiery JP, Brisken C, Riethdorf S, Alix-Panabieres C, Pantel K. Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. Embo Mol Med 2020;12: e11908. 

1. Joosse SA, Souche FR, …, Wikman H, Alix-Panabieres C, Pantel K. Chromosomal Aberrations Associated with Sequential Steps of the Metastatic Cascade in Colorectal Cancer Patients. Clin Chem 2018 Oct;64(10):1505-1512.  

1. Bidard FC, Michiels S, Riethdorf S, Mueller V, …, Pierga JY, Pantel K. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J. Nat. Cancer Inst. 2018, 110: 560-7.